
## SUPPLEMENT

**Figure S1.** Proportions of patients achieving ASDAS responses among TNFi-naïve PsA patients with PA-PRS at Week12 and Week 24 (**A**) and by HLA-B27 status at Week 12 (**B**) and Week 24 (**C**). Inactive disease = ASDAS score <1.3; major improvement = decrease in ASDAS  $\geq$ 2.0; clinically-important improvement = decrease in ASDAS  $\geq$ 1.1. *HLA-B27, human leukocyte antigen B27 allele; ASDAS, Ankylosing Spondylitis Disease Activity Score; PA-PRS, peripheral arthritis and physician-reported spondylitis; PsA, psoriatic arthritis; TNFi, tumor necrosis factor-inhibitor* 



1